|
1
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Epstein AC, Gleadle JM, McNeill LA,
Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI,
Dhanda A, et al: C. elegans EGL-9 and mammalian homologs define a
family of dioxygenases that regulate HIF by prolyl hydroxylation.
Cell. 107:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schönenberger D, Rajski M, Harlander S and
Frew IJ: Vhl deletion in renal epithelia causes HIF-1α-dependent,
HIF-2α-independent angiogenesis and constitutive diuresis.
Oncotarget. Aug 12–2016.(Epub ahead of print). View Article : Google Scholar
|
|
4
|
Triner D and Shah YM: Hypoxia-inducible
factors: A central link between inflammation and cancer. J Clin
Invest. 126:3689–3698. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo XF, Wang AY and Liu J:
HIFs-MiR-33a-Twsit1 axis can regulate invasiveness of
hepatocellular cancer cells. Eur Rev Med Pharmacol Sci.
20:3011–3016. 2016.PubMed/NCBI
|
|
6
|
Nauta TD, Duyndam MC, Weijers EM, van
Hinsbergh VM and Koolwijk P: HIF-2α Expression regulates sprout
formation into 3D fibrin matrices in prolonged hypoxia in human
microvascular endothelial cells. PLoS One. 11:e01607002016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nepal M, Gong YD, Park YR and Soh Y: An
activator of PHD2, KRH102140, decreases angiogenesis via inhibition
of HIF-1α. Cell Biochem Funct. 29:126–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao Y, Li H, Ma X, Fan Y, Ni D, Zhang Y,
Huang Q, Liu K, Li X, Wang L, et al: E2F3 upregulation promotes
tumor malignancy through the transcriptional activation of HIF-2α
in clear cell renal cell carcinoma. Oncotarget. Jul 13–2016.(Epub
ahead of print).
|
|
9
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizobuchi H, García-Castellano JM, Philip
S, Healey JH and Gorlick R: Hypoxia markers in human osteosarcoma:
An exploratory study. Clin Orthop Relat Res. 466:2052–2059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaelin WG Jr: How oxygen makes its
presence felt. Genes Dev. 16:1441–1445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu WR, Wu J and Li R: Contribution of the
GSTP1 gene polymorphism to the development of osteosarcoma in a
Chinese population. Genet Mol Res. 15:152016. View Article : Google Scholar
|
|
13
|
Bertout JA, Majmundar AJ, Gordan JD, Lam
JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL and Simon MC:
HIF2α inhibition promotes p53 pathway activity, tumor cell death,
and radiation responses. Proc Natl Acad Sci USA. 106:14391–14396.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ben-Shoshan J, Schwartz S, Luboshits G,
Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack
I, Barak A, Levkovitch-Verbin H, et al: Constitutive expression of
HIF-1α and HIF-2α in bone marrow stromal cells differentially
promotes their proangiogenic properties. Stem Cells. 26:2634–2643.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang Z, Tang Y, Jiao W, Xing Z, Guo Z,
Wang W, Xu Z and Liu Z: Nitidine chloride induces apoptosis and
inhibits tumor cell proliferation via suppressing ERK signaling
pathway in renal cancer. Food Chem Toxicol. 66:210–216. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Knowles HJ, Schaefer KL, Dirksen U and
Athanasou NA: Hypoxia and hypoglycaemia in Ewing's sarcoma and
osteosarcoma: Regulation and phenotypic effects of
hypoxia-inducible factor. BMC Cancer. 10:3722010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chatterjee B, Wolff DW, Jothi M, Mal M and
Mal AK: p38α MAPK disables KMT1A-mediated repression of myogenic
differentiation program. Skelet Muscle. 6:282016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faber AC, Coffee EM, Costa C, Dastur A,
Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, et al: mTOR
inhibition specifically sensitizes colorectal cancers with KRAS or
BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Cancer Discov. 4:42–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hua S and Dias TH: Hypoxia-Inducible
Factor (HIF) as a target for novel therapies in rheumatoid
arthritis. Front Pharmacol. 7:1842016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rogers LJ, Basnakian AG, Orloff MS, Ning
B, Yao-Borengasser A, Raj V and Kadlubar S:
2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP) induces
gene expression changes in JAK/STAT and MAPK pathways related to
inflammation, diabetes and cancer. Nutr Metab (Lond). 13:542016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi K, Li Y, Li X, Lei X, Wang B, Zhang L
and Chu X: Id4 promotes cisplatin resistance in lung cancer through
the p38 MAPK pathway. Anticancer Drugs. 27:970–978. 2016.
View Article : Google Scholar : PubMed/NCBI
|
